文摘
Lung cancer remains a major problem and will continue to be a major problem in oncology over the next number of decades. Treatment results have remained static over the past 10 to 20 years with modest improvements in overall survival. However, during that time, there has been an explosion in our knowledge of the biological and molecular events involved in the pathogenesis of lung cancer. A better understanding of these should allow the development of new therapeutic strategies for the intervention and treatment of patients with this disease. Moreover, the next decade will allow us to clearly evaluate the role that these biomarkers will have in the early detection of lung cancer and perhaps treatment results will be significantly improved.